A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

Condition:   Salmonella Infections Interventions:   Biological: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose;   Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose;   Biological: Typhoid conjugate vaccine (TCV) low dose;   Biological: Invasive non typhoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose;   Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose;   Biological: Typhoid conjugate vaccine (TCV) full dose;   Biological: GSK's Meningococcal A, C, Y and W-135 conjugate vaccine;   Combination Product: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine;   Combination Product: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine;   Drug: Placebo;   Other: Saline Sponsors:   GlaxoSmithKline;   Biomedical Advanced Research and Development Authority;   Wellcome Trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials